Clinical Trial Update: CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating CD180 CAR-T therapy for relapsed or refractory CD180-positive hematologic malignancies is currently recruiting, including acute myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CD180 CAR-T

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma | Phase 1 | Status: RECRUITING